Echtzeit-Aktienkurs Lineage Cell Therapeutics Inc.
Bid:
Ask:
Echtzeit-Chart der Lineage Cell Therapeutics Inc. Aktie
Börsenkurse Lineage Cell Therapeutics Inc.
| Echtzeit USD | - | - | - | - | - | - |
| Echtzeit Euro | - | - | - | - | - | - |
| Lang & Schwarz | - | - | - | - | 0,920€ | -1,08% |
| New York | - | - | - | - | - | - |
| Nasdaq | - | - | - | - | - | - |
| Börse Stuttgart | - | - | - | - | - | - |
| Tradegate | - | - | - | - | 0,918€ | -0,81% |
| Börse Frankfurt | - | - | - | - | 0,910€ | 2,25% |
Fundamentaldaten der Lineage Cell Therapeutics Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2023 [USD] | 8,95 Mio. | -23,28 Mio. | -21,49 Mio. | -0,12 | - | - | - |
| 2022 [USD] | 14,70 Mio. | -25,81 Mio. | -26,27 Mio. | -0,16 | - | - | - |
| 2021 [USD] | 3,90 Mio. | -43,27 Mio. | -43,02 Mio. | -0,26 | - | - | - |
| 2020 [USD] | 0,77 Mio. | -21,92 Mio. | -20,65 Mio. | -0,14 | - | - | - |
| 2019 [USD] | 1,48 Mio. | -19,23 Mio. | -11,71 Mio. | -0,08 | - | - | - |
| 2018 [USD] | 1,42 Mio. | -47,13 Mio. | -45,99 Mio. | -0,36 | - | - | - |
| 2017 [USD] | 3,46 Mio. | -23,29 Mio. | -19,98 Mio. | -0,17 | - | - | - |
| 2016 [USD] | 5,92 Mio. | 18,62 Mio. | 33,57 Mio. | 0,34 | - | - | - |
| 2015 [USD] | 7,04 Mio. | -62,65 Mio. | -46,99 Mio. | -0,59 | - | - | - |
| 2014 [USD] | 5,24 Mio. | -51,15 Mio. | -36,41 Mio. | -0,55 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Lineage Cell Therapeutics Inc. Aktie
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in